Work Packages

In order to implement all the activities of the Project, FORCE is structured in 11 Work Packages (WPs)

 

WP1 MRF reconstruction and biomarker development.  WP1 is entirely dedicated to the reconstruction of IFP and the active forces from MRF data and lasts 4 years Lead beneficiary: King’s College London, United Kingdom  (with the collaboration of King’s College Hospital and Guy’s and St Thomas’s NHS Foundation Trust)
Scientific Advisors: University of New South Wales (NeuRA), Australia Brigham and Women’s Hospital, United States
WP2 MRF preclinical sequence development. WP2 represents the preclinical MRF hardware and sequence development Lead beneficiary: Institute of Cancer Research – Royal Cancer Hospital, United Kingdom
WP3 MRF clinical sequence development. The first sequences twill be deployed to the 3 clinical sites. The details of the sequence development will be influenced by results from simulations (WP1) and TFM data (WP6) providing targets for data quality and SNR. The following years are dedicated to sequence optimization  and improved 3D strain acquisition Lead beneficiaries: Eidgenoessische Technische Hochschule Zürich, Switzerland
Charité, German
CGC Instruments, Germany
Integrated Technologies Limited, United Kingdom
Philips, Netherlands
WP4 Pre-clinical MRF Validation and investigation of Metastatic Spread. WP4 collects initially ground truth data for IFP for validation of the reconstruction method (WP1). Subsequently, MRF derived parameters will be studied to verify their usefulness in predicting the metastatic spread in a preclinical breast/liver/brain cancer model Lead beneficiary: Institute of Cancer Research – Royal Cancer Hospital, United Kingdom
WP5 Preclinical MRF for Response to Therapy. WP5 focuses on the question of predicting response to therapy via MRF quantified IFP in specific liver cancer models Lead beneficiaries: Institut National de la Santé et de la Recherche Médicale, France
Sanofi Aventis, France
WP6 Mechanical Impact of Solid Tumours on Tissues. WP6 investigates via TFM the active forces generated by tumour spheroids onto their surrounding matrix. Lead beneficiaries: Universität Leipzig, Germany
ScreenCell, France
WP7 Ultrasound-induced Mechanosignaling. WP7 is the only therapeutic WP where active processes of mechanotransduction are studied. It represents a truly exploratory workpackage that, within the consortium, uniquely leverages outcomes to examine an entirely new modality for signalling and treatment in cancer Lead beneficiary: Universitetet i Oslo, Norway

 

WP8 Microvascular involvement and Response to Therapy for HCCs predicted by MRF WP8, WP9, and WP10 are the clinical WPs for liver, brain, and breast. Clinical protocols will be developed, MRF hardware installed and sequences tested. All sites will then start with MRF data collection during the 1st phase of clinical testing. Later, newly developed sequence, protocols, and potential hardware changes will be introduced. Lead beneficiary: Assistance Publique – Hôpitaux de Paris, France
WP9 Response to therapy for brain tumours Lead beneficiary: Universitat Basel, Switzerland
WP10 Lymphnode involvement and response to therapy for breast cancer predicted by MRF Lead beneficiary: King’s College London, United Kingdom  (with the collaboration of King’s College Hospital and Guy’s and St Thomas’s NHS Foundation Trust)
WP11 Management. The last WP covers the coordination and supervision of the project, as well as all aspects related to communication, dissemination of results, valorisation of generated IP. Lead beneficiary: King’s College London, United Kingdom
Advertisements